Ophthalmology ·
Bimatoprost-eluting IOL holds 37% pressure drop at four years; FDA clears trial of RDH12 gene therapy
Listen to this post
read by AI voices · all episodesTHE SHORT READ
SpyGlass Pharma said Oct. 19 that its bimatoprost-eluting intraocular lens kept intraocular pressure 37% below baseline at four years in its first-in-human trial. The Food and Drug Administration (FDA) cleared an investigational new drug application for Opus Genetics' gene therapy for RDH12-associated Leber congenital amaurosis, the company said.
THE DETAILS
- Technology Oct 19, 2026SpyGlass Pharma said Oct. 19 that mean intraocular pressure (IOP) fell 37%, from 25.1 mm Hg at baseline to 15.9 mm Hg, at 48 months in 21 evaluable patients in its first-in-human trial of the Bimatoprost Drug Pad-IOL (BIM-IOL) System in mild-to-moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. Eighteen of 21 (86%) remained off all topical IOP-lowering drops, 90% maintained best-corrected distance visual acuity of 20/25 or better and no product-related adverse events were reported, the company said. The data are company-reported; the system is in phase 3 trials.
- FDA Oct 21, 2026Opus Genetics said Oct. 21 that the Food and Drug Administration (FDA) cleared its investigational new drug application for OPGx-RDH12, an adeno-associated virus (AAV)-based gene therapy designed to deliver a functional copy of the RDH12 gene directly to retinal photoreceptor cells. The company plans to start a phase 1/2 trial in the fourth quarter of 2026, according to Eyewire+. It is the company's third gene therapy program to enter clinical development, the company said.
The weekly innovation roundup for ophthalmology, published every Sunday for the week before; every item links to its sources. Latest ophthalmology news · All specialties